ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 6.4 | 45.3 | 0.5 |
| Other income | 0.0 | 0.1 | 0.0 |
| Total income | 6.4 | 45.3 | 0.5 |
| Profit before exceptional items & tax | -0.3 | 0.2 | -1.0 |
| Profit before tax | -0.3 | 0.2 | -1.0 |
| Net profit | -0.5 | 0.2 | -1.0 |
| Operating margin | -4.7% | 0.4% | -200.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +1180.00% |
|---|
BSE results filing, NSE: VIVANZA. Figures extracted from the filing.
Vivanza Biosciences Ltd: key numbers
- Share price
- ₹1.47
- Market cap
- ₹5.88 Cr
- Revenue (annual)
- ₹115.9 Cr
- Net profit (annual)
- ₹0.39 Cr
- P/E (TTM)
- 213.0×Sector 43.8×
- Promoter holding
- 20.02%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vivanza Biosciences Ltd
All →Vivanza Biosciences Q2 FY27 Results: Net Profit ₹0.1 Cr, Down 83.3% YoY
Vivanza Biosciences Ltd reported revenue from operations of ₹11.4 Cr (-79.4% YoY) and net profit of ₹0.1 Cr (-83.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹0.1 Cr · -83.3% YoY
Vivanza Biosciences Board Meeting Date
Vivanza Biosciences has scheduled a Board meeting on November 3, 2026 to approve unaudited Q2 and H1 FY27 financial results. No other material agenda items are listed.
Vivanza Biosciences Other Announcement
Vivanza Biosciences Ltd has filed a compliance certificate under Regulation 74(5) of SEBI (DP) Regulations for the quarter ended September 30, 2026.
Vivanza Biosciences Annual General Meeting
Vivanza Biosciences has convened its 44th AGM on September 11, 2026 via VC/OAVM. Nine agenda items cover financial statements, director appointments, and borrowing limit approvals.
Vivanza Biosciences Annual Report
Vivanza Biosciences Limited has scheduled its 44th Annual General Meeting for September 11, 2026. The company also released its full Annual Report for the financial year 2025-26.
Vivanza Biosciences Board Meeting Outcome
Vivanza Biosciences approved its annual reports, the convening of the 44th AGM, and various procedural resolutions including borrowing limits and related party transactions for upcoming periods.